Effects of Cladribine Tablets on the PK of Microgynon®
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the potential effects of cladribine on the
pharmacokinetics (PK) of monophasic oral contraceptive microgynon® by assessment of its
constituents, ethinyl estradiol (EE) and levonorgestrel (LNG).
Phase:
Phase 1
Details
Lead Sponsor:
Merck KGaA Merck KGaA, Darmstadt, Germany
Treatments:
Cladribine Ethinyl Estradiol-Norgestrel Combination Ethinyl estradiol, levonorgestrel drug combination